Lido Advisors’s AEON Biopharma AEON Stock Holding History

Lido Advisors’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-179	Closed	-$6.96K	–	1512
2024 Q4	$6.96K	Hold	179	–	–	﹤0.01%	1493
2024 Q3	$13.5K	Buy	+179	New	+$15.8K	﹤0.01%	1452

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Lido Advisors's AEON Position: Q1 2025 in Review

Lido Advisors sold out of AEON Biopharma (AEON) in Q1 2025, closing a stake of 179 shares — an estimated $6.96K sold.

Lido Advisors first reported a position in AEON in Q3 2024 and held it in 2 quarters. The position peaked at $13.5K in Q3 2024. 16 funds tracked by Wall St. Rank hold AEON as of Q1 2025.

Lido Advisors reported no remaining AEON Biopharma position as of Q1 2025 after selling out during the quarter.
Lido Advisors sold 179 AEON Biopharma shares in Q1 2025, an estimated $6.96K.
Lido Advisors first reported a position in AEON Biopharma in Q3 2024 and held it in 2 quarters.
Lido Advisors's AEON Biopharma position peaked at $13.5K in Q3 2024.
16 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2025.

Based on Lido Advisors's 13F filing for Q1 2025, filed 15 May 2025.